Study of High Dose Interleukin-2 (IL-2) and Stereotactic Body Radiation (SBRT) in Patients With Metastatic Renal Cancer

Renal Cell Carcinoma Clinical Trial

Official title:

Phase II Randomized Study of High Dose Interleukin-2 Versus Stereotactic Body Radiation (SBRT) and High Dose Interleukin-2 (IL-2) in Patients With Metastatic Renal Cancer

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02306954
• Other study ID #: 14-256A
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: December 2014
• Est. completion date: December 2026

Study information

• Verified date: January 2024
• Source: Providence Health & Services
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

All patients will receive IL-2 (14 planned doses with an additional cycle 14 days after the first). Responding patients with regressing disease are eligible for up to 6 IL-2 cycles. Patients assigned to SBRT arm will receive two doses of SBRT on the Wednesday and Friday before the Monday on which IL-2 starts.

Description:

All patients will receive IL-2 at 600,000 international units per kilogram (kg) by intraveneous bolus (IVB) every 8 hours for 14 planned doses with an additional cycle 14 days after the first. Responding patients with regressing disease are eligible for up to 6 IL-2 cycles. Patients assigned to SBRT arm will receive two doses of SBRT at 20 Gray (Gy) on the Wednesday and Friday before the Monday on which IL-2 starts.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 84
• Est. completion date: December 2026
• Est. primary completion date: December 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histological confirmation of predominant conventional (clear cell) renal cancer

• Patients must be = 18 years of age

• Tumors amenable to SBRT in lungs (central locations preferred), mediastinum, chest wall, bones with a soft tissue component (other than long bones), or liver, liver hilum and associated lymph nodes (inclusive of immediately adjacent masses), 1 - 3 foci; no minimum size, but none greater than 7 cm. Patients may have other metastases but only a maximum of 3 will be treated

• Eastern Cooperative Oncology Group (ECOG) performance status of 0-1

• Women of childbearing potential must have a negative serum or urine pregnancy test within 72 hours prior to the start of protocol treatment. In addition, women of childbearing potential as well as male patients must agree to take appropriate precautions to avoid pregnancy

• Patients must agree to participate in the Prometheus IL-2 patient registry (PROCLAIM registry)

• Patients must sign a study-specific consent form

Exclusion Criteria:

• No metastatic site amenable to SBRT

• Patients with brain metastases not candidates for radiosurgery alone

• Previous radiation to sites proposed for SBRT

• Patients with active systemic, pulmonary, or pericardial infection

• Pregnant or lactating women, as treatment involves unforeseeable risks to the embryo or fetus

• Evidence of ischemia on exercise tolerance test, stress thallium study, or baseline EKG

• Clinically significant underlying pulmonary disease as measured by pulmonary function tests

• Blood tests within protocol-specified range

• Need for chronic steroids

Related Conditions & MeSH terms

• Carcinoma, Renal Cell
• Kidney Neoplasms
• Renal Cell Carcinoma

Intervention

Biological:
• High Dose IL-2
High Dose IL-2 is approved by the FDA for the treatment of renal cell cancer.

Radiation:
• SBRT
Patients assigned to SBRT arm will receive two doses of SBRT at 20 Gy on the Wednesday and Friday before the Monday on which IL-2 starts.

Locations

Country	Name	City	State
United States	Portland Providence Medical Center	Portland	Oregon

Sponsors (3)

Lead Sponsor	Collaborator
Providence Health & Services	Cytokine Working Group, Prometheus Laboratories

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Response Rate	The objective of this study is to compare the response rate among renal cell cancer (RCC) patients of high dose IL-2 to SBRT + IL-2 in patients with metastatic renal cancer	5 years
Secondary	Response Rate in Patients Who Receive SBRT following Progression on IL-2	Measure the response of SBRT + IL-2 in patients with RCC who have disease progression after high-dose IL-2	5 years

External Links

•   Providence Cancer Center